CAIMH
RXRX icon

Central Asset Investments & Management Holdings’s Recursion Pharmaceuticals RXRX Stock Holding History

Central Asset Investments & Management Holdings’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,200
Closed -$96K – 71
2024
Q4 		$96K Buy
+14,200
New +$95.5K 0.06% 75

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Central Asset Investments & Management Holdings's RXRX Position: Q1 2025 in Review

Central Asset Investments & Management Holdings sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 14,200 shares — an estimated $96K sold.

Central Asset Investments & Management Holdings first reported a position in RXRX in Q4 2024 and held it in 1 quarter. The position peaked at $96K in Q4 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Central Asset Investments & Management Holdings reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Central Asset Investments & Management Holdings sold 14,200 Recursion Pharmaceuticals shares in Q1 2025, an estimated $96K.
  • Central Asset Investments & Management Holdings first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Central Asset Investments & Management Holdings's Recursion Pharmaceuticals position peaked at $96K in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Central Asset Investments & Management Holdings's 13F filing for Q1 2025, filed 13 May 2025.